Millipore Sigma Vibrant Logo

HCKP1-11K-PX17 MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Premixed 17-plex Panel 1 - Immuno-Oncology Multiplex Assay

The Human Immuno-Oncology Checkpoint Protein Panel 1 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 17 immune checkpoint proteins in human serum, plasma and cell culture samples.

MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.
Key Applications: Multiplexing Detection Methods: Luminex xMAP Research Category: Oncology Research Sub-Category: Immune Response, Inflammation, Tumor Markers
View Products on Sigmaaldrich.com
HCKP1-11K-PX17
96-well plate  96 well plate
Ricerca del prezzo in corso...
Non è stato possibile trovare il prezzo
La quantità minima deve essere un multiplo di
Maximum Quantity is
Al termine dell'ordine Maggiori informazioni
Lei ha salvato ()
 
—
Richiedi il prezzo
—
Disponibilità limitata Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

       

      Contatti il Servizio Clienti

      Panoramica

      Replacement Information

      Tabella delle specifiche principali

      Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
      BTLA CD27 CD28 CD40 CD80/B7-1 CD86/B7-2 CTLA-4 GITR GITRL HVEM ICOS LAG-3 PD-1 PD-L1 PD-L2 TIM-3 TLR-2 HMplexLuminex xMAP
      Description
      Catalogue NumberHCKP1-11K-PX17
      Trade Name
      • MILLIPLEX
      DescriptionMILLIPLEX® Human Immuno-Oncology Checkpoint Protein Premixed 17-plex Panel 1 - Immuno-Oncology Multiplex Assay
      OverviewThe MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 1 is a 17-plex kit to be used for the simultaneous quantification of all of the following analytes in serum, plasma and tissue culture samples: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2).
      Background InformationImmune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies.

      Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.
      References
      Product Information
      Detection methodLuminex xMAP
      ConfigurationPremixed
      Precision, %
      • Inter-assay: <15
      • Intra-assay: <5
      Panel TypeMAGNETIC Circulating Cancer
      Applications
      ApplicationThe Human Immuno-Oncology Checkpoint Protein Panel 1 bead-based multiplex panel, using the Luminex xMAP technology, enables the simultaneous analysis of 17 immune checkpoint proteins in human serum, plasma and cell culture samples.
      Key Applications
      • Multiplexing
      Application NotesFor optimal sensitivity, use an overnight (16-18 hour) incubation. Serum and plasma samples require (recommended) a 1:2 dilution with Assay Buffer. Tissue culture supernatants may be run neat or appropriately diluted in control medium. Each well requires 25 μL of sample, standard or control.
      Biological Information
      SpecificityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
      Species Reactivity
      • Human
      Analytes Available
      • BTLA
      • CD27
      • CD28
      • CD40
      • CD80/B7-1
      • CD86/B7-2
      • CTLA-4
      • GITR
      • GITRL
      • HVEM
      • ICOS
      • LAG-3
      • PD-1
      • PD-L1
      • PD-L2
      • TIM-3
      • TLR-2
      Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
      Accuracy
      • BTLA: 95%
      • CD27: 96%
      • CD28: 95%
      • CD40: 97%
      • CD80/B7-1: 96%
      • CD86/B7-2: 98%
      • CTLA-4: 95%
      • GITR: 90%
      • GITRL: 103%
      • HVEM: 98%
      • ICOS: 100%
      • LAG-3: 97%
      • PD-1: 97%
      • PD-L1: 97%
      • PD-L2: 102%
      • TIM-3: 98%
      • TLR-2: 95%
      Physicochemical Information
      Sensitivity
      • (minDC+ 2SD)
      • BTLA: 43.8 pg/mL
      • CD27: 24.1 pg/mL
      • CD28: 84.5 pg/mL
      • CD40: 4.3 pg/mL
      • CD80/B7-1: 11.2 pg/mL
      • CD86/B7-2: 86.1 pg/mL
      • CTLA-4: 9.3 pg/mL
      • GITR: 18.8 pg/mL
      • GITRL: 20.5 pg/mL
      • HVEM: 0.8 pg/mL
      • ICOS: 55.6 pg/mL
      • LAG-3: 66.0 pg/mL
      • PD-1: 13.7 pg/mL
      • PD-L1: 1.3 pg/mL
      • PD-L2: 46.6 pg/mL
      • TIM-3: 1.5 pg/mL
      • TLR-2: 24.1 pg/mL
      Standard Curve Range
      • BTLA: 49 – 200,000 pg/mL
      • CD27: 24 – 100,000 pg/mL
      • CD28: 244 – 1,000,000 pg/mL
      • CD40: 5 – 20,000 pg/mL
      • CD80/B7-1: 12 – 50,000 pg/mL
      • CD86/B7-2: 73 – 300,000 pg/mL
      • CTLA-4: 12 – 50,000 pg/mL
      • GITR: 5 – 20,000 pg/mL
      • GITRL: 24 – 100,000 pg/mL
      • HVEM: 2 – 10,000 pg/mL
      • ICOS: 49 – 200,000 pg/mL
      • LAG-3: 122 – 500,000 pg/mL
      • PD-1: 24 – 100,000 pg/mL
      • PD-L1: 5 – 20,000 pg/mL
      • PD-L2: 49 – 200,000 pg/mL
      • TIM-3: 5 – 20,000 pg/mL
      • TLR-2: 73 – 300,000 pg/mL
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsRecommended storage for kit components is 2 - 8°C.
      Packaging Information
      Material Size96-well plate
      Material Package96 well plate
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      HCKP1-11K-PX17 04061841002239